Wednesday, April 06, 2022 9:46:49 AM
Phase 2 Clinical Trial of TNX-102 SL for the Treatment of Long COVID Expected to Start Second Quarter 2022
Long COVID Afflicts More Than 30% of Patients Following Infection with SARS-CoV-2, the Virus that Causes COVID-19, and is Expected to be a Global Health Burden
CHATHAM, N.J., April 06, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to support a Phase 2 clinical trial with TNX-102 SL1 as a potential treatment for a subset of patients with Long COVID Syndrome (Long COVID) whose symptoms overlap with fibromyalgia. Long COVID is now known officially as Post-Acute Sequelae of COVID-19 (PASC2).
“We are excited to have received the FDA’s IND clearance to begin clinical trials of TNX-102 SL for the treatment of Long COVID,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Over 30% of people who recover from COVID-19 continue to experience a constellation of symptoms long past the time that they have recovered from acute COVID-19 illness3-4. The symptoms of Long COVID, which can include fatigue, multi-site pain, sleep disturbances, fevers, shortness of breath, cognitive impairment, gastrointestinal symptoms, anxiety, and depression, can persist for many months and can range from mild to incapacitating5. Our study will focus on testing TNX-102 SL in the treatment of patients with multi-site pain associated with Long COVID. This group of patients have symptoms that overlap with other chronic pain conditions, which as a group have been termed, ‘chronic overlapping pain conditions.’6,7 This type of pain syndrome is increasingly recognized as nociplastic pain,8 and the underlying mechanism as ‘central sensitization.’9 Fibromyalgia is considered one of the chronic overlapping pain conditions and our experience with TNX-102 SL in fibromyalgia is the motivation for undertaking the development of TNX-102 SL in patients with Long COVID whose symptoms overlap with fibromyalgia.”
About the Phase 2 Study
This Phase 2 study will be a double-blind randomized, placebo-controlled 14-week trial to evaluate the safety and efficacy of sublingual TNX-102 SL 5.6 mg daily at bedtime in the treatment of patients with multi-site pain associated with Long COVID. The trial will be conducted at approximately 30 sites to enroll approximately 470 patients (235 per arm) who will be randomized in a 1:1 ratio to treatment with TNX-102 SL or placebo tablets. The primary efficacy endpoint will be Change from Baseline in the weekly average of daily self-reported worst pain intensity scores at the Week 14 endpoint. An interim analysis is expected to be completed after the first 50% of enrolled patients have completed the study for the purpose of possible sample size re-estimation.
About Long COVID or Post-Acute Sequelae of SARS-CoV-2 (PASC)
Although most people recover from COVID-19 within weeks of the acute illness, a substantial portion develop a chronic syndrome called Long COVID. These individuals experience a constellation of disabling symptoms long past the time of recovery from acute COVID-19. Most Long COVID patients who have been studied appear to have cleared the SARS-CoV-2 infection from their systems. The symptoms of Long COVID can include fatigue, sleep disorders, multi-site pain, fevers, shortness of breath, cognitive impairment described as “brain fog” or memory disturbance, gastrointestinal symptoms, anxiety, and depression. Long COVID can persist for many months and can range in severity from mild to incapacitating. Several cohort studies have reported that persistence of symptoms following SARS-CoV-2 infection occurs in more than 30% of patients.3-5 While typically associated with moderate or severe COVID-19, Long COVID can occur after mild COVID-19 or even after asymptomatic SARS-CoV-2 infection. Patients with Long COVID are sometimes referred to as “long-haulers”. Long COVID is a chronic disabling condition that is expected to result in a significant global health and economic burden.10-13 In response to the urgent need for therapies that address Long COVID, Congress awarded $1.15 billion to the National Institutes of Health to study Long COVID in December 2020.14 While the vaccines available in the U.S. through either FDA approval or under Emergency Use Authorization have been shown to prevent acute COVID, their ability to prevent Long COVID is unknown. There is currently no approved drug for the treatment of Long COVID.
https://ca.finance.yahoo.com/news/tonix-pharmaceuticals-announces-ind-clearance-110000535.html
Recent TNXP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 11:23:27 AM
- Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency • GlobeNewswire Inc. • 09/16/2024 11:00:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/13/2024 09:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 11:05:24 AM
- Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations • GlobeNewswire Inc. • 09/10/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 11:07:15 AM
- Tonix Pharmaceuticals Presented Data on the Potential Mpox Vaccine TNX-801 in “Using Synthetic Biology to Battle Mpox” Talk at Immunology Symposium at the University of Alberta • GlobeNewswire Inc. • 09/09/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 09:17:58 PM
- Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek • GlobeNewswire Inc. • 09/06/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 09:08:17 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/30/2024 09:04:45 PM
- Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS) • GlobeNewswire Inc. • 08/29/2024 11:00:00 AM
- Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium (MHSRS) • GlobeNewswire Inc. • 08/28/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 11:05:17 AM
- Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix’s Mpox Vaccine, TNX-801 • GlobeNewswire Inc. • 08/26/2024 11:00:00 AM
- Tonix Pharmaceuticals Announces Oral Presentation and Three Poster Presentations at the 2024 Military Health System Research Symposium (MHSRS) • GlobeNewswire Inc. • 08/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 11:05:23 AM
- Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication • GlobeNewswire Inc. • 08/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 10:05:58 AM
- Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights • GlobeNewswire Inc. • 08/19/2024 10:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/16/2024 09:18:38 PM
- Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health Emergency • GlobeNewswire Inc. • 08/16/2024 11:00:00 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2024 10:03:25 AM
- Tonix Pharmaceuticals to Present at the Summer 2024 Virtual Investor Summit • GlobeNewswire Inc. • 08/13/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:18:07 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM